Tokyo, Japan, October 7, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that Astellas and Boehringer Ingelheim Pharmaceuticals, Inc. (a US subsidiary of Boehringer Ingelheim (headquarters: Germany), “BIPI”) have reached agreement with Impax Laboratories, Inc. (“Impax”) to settle pending U.S. litigation with regard to US Patent No. 4,703,063 for FLOMAX^® (generic name: tamsulosin hydrochloride capsules, brand name in Japan: Harnal^®) through the entry of a consent judgment confirming the validity and infringement of the patent. FLOMAX is a treatment for the functional symptoms of benign prostatic hyperplasia.